Article Versions Notes

Zhao J, Han L, Zhang Y-R, Liu S-M, Ji D-R, Wang R, Yu Y-R, Jia M-Z, Chai S-B, Tang H-F, et al. Intermedin Alleviates Diabetic Cardiomyopathy by Up-Regulating CPT-1β through Activation of the Phosphatidyl Inositol 3 Kinase/Protein Kinase B Signaling Pathway. Pharmaceuticals. 2024; 17(9):1204. https://doi.org/10.3390/ph17091204

Zhao, Jie, Ling Han, Ya-Rong Zhang, Shi-Meng Liu, Deng-Ren Ji, Rui Wang, Yan-Rong Yu, Mo-Zhi Jia, San-Bao Chai, Hui-Fang Tang, and et al. 2024. "Intermedin Alleviates Diabetic Cardiomyopathy by Up-Regulating CPT-1β through Activation of the Phosphatidyl Inositol 3 Kinase/Protein Kinase B Signaling Pathway" Pharmaceuticals 17, no. 9: 1204. https://doi.org/10.3390/ph17091204

Zhao, J., Han, L., Zhang, Y.-R., Liu, S.-M., Ji, D.-R., Wang, R., Yu, Y.-R., Jia, M.-Z., Chai, S.-B., Tang, H.-F., Huang, W., & Qi, Y.-F. (2024). Intermedin Alleviates Diabetic Cardiomyopathy by Up-Regulating CPT-1β through Activation of the Phosphatidyl Inositol 3 Kinase/Protein Kinase B Signaling Pathway. Pharmaceuticals, 17(9), 1204. https://doi.org/10.3390/ph17091204